Company Overview and News
Having been a contributor on Seeking Alpha for over a year, I wanted to lay out my results for public scrutiny.
WFCNP GIS AOBC WFC.PRL CRI WFC.PRJ WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN SAFM WELL WFC.PRY FSLR WFC.PRX WFC.PRW WFC.PRV MPW VTR WFC WFC.WS DOC ROST AAON NHI
46 of 106 Dividend Achievers (10 or more years of higher dividends) were tagged "safer" because they showed positive annual-returns, and free cash-flow yields greater than dividend yields 6/4/18.
DLR.PRH HEP DLR.PRG DLR.PRJ DLR.PRI O.PRF OPRF VZA WELL LEG WHG O CMI NNN.PRD NNN.PRF NNN.PRE PEP JNJ ORI CVX LAZ VZ DLR WPC QCOM NHI DLR.PRC NNN DLR.PRF IVZ
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Document UNITED STATES
Document UNITED STATES
I write for the individual, ordinary investor who wants to manage or monitor their own income stocks. In this post I am looking at stocks that I call my "5 percenters." These stocks are intended for retirement accounts. Therefore, the universe of stocks does not include master limited partnerships due to their complicated tax implications.
T JNJ NHI
Sabra Healthcare Inc. (SBRA) has had its stock price beaten down along with other healthcare real estate companies over the last four months. Many investors do not want to bother with such a laggard. For those up to the challenge, here is a look under the hood.
CTRE LTC GEN CCP NHI
In 2016, Dropbox made a big announcement when it turned free cash flow positive — an important metric that shows a company has a strong financial position. But Dropbox's milestone may have been, in part, overstated with the help of some financial engineering.
13h - Asif
Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...
13h - Asif
Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
Silicon Investor Message Boards
This table lists all message boards related to NHI / National Health Investors, Inc. on message board site Silicon Investor.
as of ET